NHS
North East and
North Cumbria

30 day NICE TA recommendation from May 2024

Summary of decisions made regarding 30-day NICE TA971

Recommendations without significant financial/commissioning impact

NICE Technology Appraisal/Guidance/Drug	Date published	Current formulary status or pathway/ guidance relevance	Decision
TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 **Commissioning: ICS, tariff-excluded (remdesivir)** Remdesivir is recommended as an option for treating COVID-19 in hospitals in: • adults, only if they have a high risk of serious illness (risk factors as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19) • babies, children and young people, only if they: ○ are aged 4 weeks to 17 years and weigh at least 3 kg, and: ▪ have pneumonia, and ▪ need supplemental oxygen, or ○ weigh at least 40 kg, and have a high risk of serious illness (risk factors as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19). Remdesivir is only recommended if the company provides it according to the commercial arrangement. Tixagevimab plus cilgavimab is not recommended, within its marketing authorisation, for treating COVID-19 in adults who do not need supplemental oxygen and who have an increased risk of progression to severe COVID-19.	08/05/2024	Not currently listed.	Add to Remdesivir to the formulary as a RED drug in this indication with a link to TA971. No significant cost impact expected. Trusts have indicated that already using as per NICE TA and previous interim NHSE commissioning policy. Remdesivir has been available through the early access to medicines scheme. Therefore should not create an additional cost pressure. Remdesivir is a tariff excluded drug and as such falls within block contracts for Trusts. This guidance will have resource implications at a local level which cannot be outlined due to commercial in confidence data and uncertainty around patient populations. Therefore, encourage organisations to evaluate their own practices against the recommendations in the NICE guidance and assess costs and impact on capacity by using the NICE local resource impact template. Individual organisations, if they find it creates an unsustainable pressure to flag it through system Directors of Finance as they would do with any other unmanageable pressure. The list price of remdesivir has a commercial agreement (simple discount patient access scheme). This makes remdesivir available to the NHS with a discount. The size of the discount is commercial in confidence. The discounted prices of remdesivir can be input into the template and other variables such as prevalence figures may be amended. Approved by NENC ICB Chief Pharmacist 6.6.2024.

Key for Recommended RAG status: Not Approved (DNP), Green – suitable for prescribing in primary care; Specialist Initiation/Recommendation – should be started or recommended by a specialist but suitable for ongoing prescribing in primary care; Shared Care – suitable for prescribing under an agreed shared care protocol; or Red – not suitable for prescribing in primary care.